Emmaus Medical Announces Completion of Enrollment for its Phase 3 Sickle Cell Disease Trial

December 03, 2012

TORRANCE, Calif., December 3, 2012 – Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.